The Food and Drug Administration’The Food and Drug Administration’s approval in 2023 of lecanemab — a novel Alzheimer’s therapy shown in clinical trials to modestly slow disease progression — was met with enthusiasm by many in the field as it represented the first medication of its kind able to influence the disease. But side effects […]
Drug to slow Alzheimer’s well tolerated outside of clinical trial setting
